|
1
|
Sinaii N, Cleary SD, Ballweg ML, Nieman LK
and Stratton P: High rates of autoimmune and endocrine disorders,
fibromyalgia, chronic fatigue syndrome and atopic diseases among
women with endometriosis: A survey analysis. Hum Reprod.
17:2715–2724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
NHS Choices Endometriosis-NHS Choices.
http://www.nhs.uk/conditions/endometriosis/pages/introduction.aspx.
Accessed June 1, 2016.
|
|
3
|
Sainz de la Cuesta R, Eichhorn JH, Rice
LW, Fuller AF Jr, Nikrui N and Goff BA: Histologic transformation
of benign endometriosis to early epithelial ovarian cancer. Gynecol
Oncol. 60:238–244. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart LM, Holman CD, Aboagye-Sarfo P,
Finn JC, Preen DB and Hart R: In vitro fertilization,
endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol.
128:260–264. 2013. View Article : Google Scholar
|
|
5
|
Pearce CL, Templeman C, Rossing MA, Lee A,
Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund
KG, et al: Association between endometriosis and risk of
histological subtypes of ovarian cancer: A pooled analysis of
case-control studies. Lancet Oncol. 13:385–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu AH, Pearce CL, Tseng CC, Templeman C
and Pike MC: Markers of inflammation and risk of ovarian cancer in
Los Angeles County. Int J Cancer. 124:1409–1415. 2009. View Article : Google Scholar
|
|
7
|
Merritt MA, Green AC, Nagle CM and Webb
PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian
Cancer Study Group: Talcum powder, chronic pelvic inflammation and
NSAIDs in relation to risk of epithelial ovarian cancer. Int J
Cancer. 122:170–176. 2008. View Article : Google Scholar
|
|
8
|
Melin A, Sparén P, Persson I and Bergqvist
A: Endometriosis and the risk of cancer with special emphasis on
ovarian cancer. Hum Reprod. 21:1237–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Borgfeldt C and Andolf E: Cancer risk
after hospital discharge diagnosis of benign ovarian cysts and
endometriosis. Acta Obstet Gynecol Scand. 83:395–400. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rossing MA, Cushing-Haugen KL, Wicklund
KG, Doherty JA and Weiss NS: Risk of epithelial ovarian cancer in
relation to benign ovarian conditions and ovarian surgery. Cancer
Causes Control. 19:1357–1364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brinton LA, Gridley G, Persson I, Baron J
and Bergqvist A: Cancer risk after a hospital discharge diagnosis
of endometriosis. Am J Obstet Gynecol. 176:572–579. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brinton LA, Lamb EJ, Moghissi KS, Scoccia
B, Althuis MD, Mabie JE and Westhoff CL: Ovarian cancer risk
associated with varying causes of infertility. Fertil Steril.
82:405–414. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brinton LA, Sakoda LC, Sherman ME,
Frederiksen K, Kjaer SK, Graubard BI, Olsen JH and Mellemkjaer L:
Relationship of benign gynecologic diseases to subsequent risk of
ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev.
14:2929–2935. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar
|
|
16
|
Rogers-Broadway KR, Chudasama D, Pados G,
Tsolakidis D, Goumenou A, Hall M and Karteris E: Differential
effects of rapalogues, dual kinase inhibitors on human ovarian
carcinoma cells in vitro. Int J Oncol. 49:133–143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leconte M, Nicco C, Ngô C, Chéreau C,
Chouzenoux S, Marut W, Guibourdenche J, Arkwright S, Weill B,
Chapron C, et al: The mTOR/AKT inhibitor temsirolimus prevents deep
infiltrating endometriosis in mice. Am J Pathol. 179:880–889. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Afshar Y, Hastings J, Roqueiro D, Jeong
JW, Giudice LC and Fazleabas AT: Changes in eutopic endometrial
gene expression during the progression of experimental
endometriosis in the baboon Papio anubis. Biol Reprod. 88:442013.
View Article : Google Scholar
|
|
19
|
Potter CJ, Pedraza LG and Xu T: Akt
regulates growth by directly phosphorylating Tsc2. Nat Cell Biol.
4:658–665. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Manning BD, Tee AR, Logsdon MN, Blenis J
and Cantley LC: Identification of the tuberous sclerosis complex-2
tumor suppressor gene product tuberin as a target of the
phos-phoinositide 3-kinase/akt pathway. Mol Cell. 10:151–162. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma XM and Blenis J: Molecular mechanisms
of mTOR-mediated translational control. Nat Rev Mol Cell Biol.
10:307–318. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo J, Gao J, Yu X, Luo H, Xiong X and
Huang O: Expression of DJ-1 and mTOR in eutopic and ectopic
endometria of patients with endometriosis and adenomyosis. Gynecol
Obstet Invest. 79:195–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Foster H, Coley HM, Goumenou A, Pados G,
Harvey A and Karteris E: Differential expression of mTOR signalling
components in drug resistance in ovarian cancer. Anticancer Res.
30:3529–3534. 2010.PubMed/NCBI
|
|
24
|
Chudasama D, Bo V, Hall M, Anikin V,
Jeyaneethi J, Gregory J, Pados G, Tucker A, Harvey A, Pink R and
Karteris E: Identification of cancer biomarkers of prognostic value
using specific gene regulatory networks (GRN): A novel role of
RAD51AP1 for ovarian and lung cancers. Carcinogenesis. 39:407–417.
2018. View Article : Google Scholar :
|
|
25
|
Hendrix ND, Wu R, Kuick R, Schwartz DR,
Fearon ER and Cho KR: Fibroblast growth factor 9 has oncogenic
activity and is a downstream target of Wnt signaling in ovarian
endometrioid adenocarcinomas. Cancer Res. 66:1354–1362. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vivian J, Rao AA, Nothaft FA, Ketchum C,
Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD,
Musselman-Brown A, et al: Toil enables reproducible, open source,
big biomedical data analyses. Nat Biotechnol. 35:314–316. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Zhu L, Kuokkanen S and Pollard JW:
Activation of protein synthesis in mouse uterine epithelial cells
by estradiol-17β is mediated by a PKC-ERK1/2-mTOR signaling
pathway. Proc Natl Acad Sci USA. 112:1382–1391. 2015. View Article : Google Scholar
|
|
28
|
Alayev A, Salamon RS, Berger SM, Schwartz
NS, Cuesta R, Snyder RB and Holz MK: mTORC1 directly phosphorylates
and activates ERα upon estrogen stimulation. Oncogene.
35:3535–3543. 2016. View Article : Google Scholar
|
|
29
|
Kim HS, Kim TH, Chung HH and Song YS: Risk
and prognosis of ovarian cancer in women with endometriosis: A
meta-analysis. Br J Cancer. 110:1878–1890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dinulescu DM, Ince TA, Quade BJ, Shafer
SA, Crowley D and Jacks T: Role of K-ras and Pten in the
development of mouse models of endometriosis and endometrioid
ovarian cancer. Nat Med. 11:63–70. 2005. View Article : Google Scholar
|
|
31
|
Laudański P, Kowalczuk O,
Klasa-Mazurkiewicz D, Milczek T, Rysak-Luberowicz D, Garbowicz M,
Baranowski W, Charkiewicz R, Szamatowicz J and Chyczewski L:
Selective gene expression profiling of mTOR-associated tumor
suppressor and oncogenes in ovarian cancer. Folia Histochem
Cytobiol. 49:317–324. 2011. View Article : Google Scholar
|
|
32
|
De Marco C, Rinaldo N, Bruni P, Malzoni C,
Zullo F, Fabiani F, Losito S, Scrima M, Marino FZ, Franco R, et al:
Multiple genetic alterations within the PI3K pathway are
responsible for AKT activation in patients with ovarian carcinoma.
PLoS One. 8:e553622013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shahrabi-Farahani M, Shahbazi S, Mahdian R
and Amini-Moghaddam S: K-Ras 4A Transcript variant is up-regulated
in eutopic endometrium of endometriosis patients during
proliferative phase of menstrual cycle. Arch Gynecol Obstet.
292:225–229. 2015. View Article : Google Scholar
|
|
34
|
Amemiyaa S, Sekizawaa A, Otsukaa J,
Tachikawa T, Saito H and Okai T: Malignant transformation of
endometriosis and genetic alterations of K-ras and microsatellite
instability. Int J Gynaecol Obstet. 86:371–376. 2004. View Article : Google Scholar
|
|
35
|
Er TK, Su YF, Wu CC, Chen CC, Wang J,
Hsieh TH, Herreros-Villanueva M, Chen WT, Chen YT, Liu TC, et al:
Targeted next-generation sequencing for molecular diagnosis of
endometriosis-associated ovarian cancer. J Mol Med (Berl).
94:835–847. 2016. View Article : Google Scholar
|
|
36
|
Peterson TR, Laplante M, Thoreen CC,
Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an
mTOR inhibitor frequently overexpressed in multiple myeloma cells
and required for their survival. Cell. 137:873–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kazi AA, Hong-Brown L, Lang SM and Lang
CH: Deptor knockdown enhances mTOR Activity and protein synthesis
in myocytes and ameliorates disuse muscle atrophy. Mol Med.
17:925–936. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pei L, Xie P, Zhou E, Yang Q, Luo Y and
Tang Z: Overexpression of DEP domain containing mTOR-interacting
protein correlates with poor prognosis in differentiated thyroid
carcinoma. Mol Med Rep. 4:817–823. 2011.PubMed/NCBI
|
|
39
|
Wang Z, Zhong J, Inuzuka H, Gao D, Shaik
S, Sarkar FH and Wei W: An evolving role for DEPTOR in tumor
development and progression. Neoplasia. 14:368–375. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Catena V and Fanciulli M: Deptor: Not only
a mTOR inhibitor. J Exp Clin Cancer Res. 36(12): 2017
|
|
41
|
Chudasama DY, Freydina DV, Freidin MB,
Leung M, Montero Fernandez A, Rice A, Nicholson AG, Karteris E,
Anikin V and Lim E: Inertia based microfluidic capture and
characterisation of circulating tumour cells for the diagnosis of
lung cancer. Ann Transl Med. 4:4802016. View Article : Google Scholar
|
|
42
|
Chudasama D, Burnside N, Beeson J,
Karteris E, Rice A and Anikin V: Perioperative detection of
circulating tumour cells in patients with lung cancer. Oncol Lett.
14:1281–1286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mabuchi S, Altomare DA, Cheung M, Zhang L,
Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF and Testa JR:
RAD001 inhibits human ovarian cancer cell proliferation, enhances
cisplatin-induced apoptosis, and prolongs survival in an ovarian
cancer model. Clin Cancer Res. 13:4261–4270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Grunt TW and Mariani GL: Novel approaches
for molecular targeted therapy of breast cancer: Interfering with
PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 13:188–204.
2013. View Article : Google Scholar
|
